Fintel reports that on October 6, 2023, Oppenheimer initiated coverage of Sutro Biopharma (NASDAQ:STRO) with a Outperform recommendation.
Analyst Price Forecast Suggests 435.65% Upside
As of October 5, 2023, the average one-year price target for Sutro Biopharma is 18.10. The forecasts range from a low of 8.08 to a high of $27.30. The average price target represents an increase of 435.65% from its latest reported closing price of 3.38.
See our leaderboard of companies with the largest price target upside.
The projected annual revenue for Sutro Biopharma is 60MM, an increase of 5.46%. The projected annual non-GAAP EPS is -2.61.
What is the Fund Sentiment?
There are 294 funds or institutions reporting positions in Sutro Biopharma. This is a decrease of 3 owner(s) or 1.01% in the last quarter. Average portfolio weight of all funds dedicated to STRO is 0.05%, a decrease of 1.71%. Total shares owned by institutions increased in the last three months by 1.18% to 58,687K shares. 
The put/call ratio of STRO is 0.28, indicating a bullish outlook.
What are Other Shareholders Doing?
Suvretta Capital Management holds 5,884K shares representing 9.72% ownership of the company. In it's prior filing, the firm reported owning 5,689K shares, representing an increase of 3.31%. The firm increased its portfolio allocation in STRO by 31.75% over the last quarter.
Rubric Capital Management holds 4,049K shares representing 6.69% ownership of the company. In it's prior filing, the firm reported owning 4,360K shares, representing a decrease of 7.70%. The firm increased its portfolio allocation in STRO by 54.12% over the last quarter.
Bvf holds 3,348K shares representing 5.53% ownership of the company. No change in the last quarter.
Franklin Resources holds 2,868K shares representing 4.74% ownership of the company. In it's prior filing, the firm reported owning 2,838K shares, representing an increase of 1.03%. The firm increased its portfolio allocation in STRO by 334.42% over the last quarter.
Holocene Advisors holds 2,133K shares representing 3.52% ownership of the company. No change in the last quarter.
Sutro Biopharma Background Information
(This description is provided by the company.)
Sutro Biopharma, Inc., located in South San Francisco, is a clinical-stage drug discovery, development and manufacturing company. Using precise protein engineering and rational design, Sutro is advancing next-generation oncology therapeutics.
Fintel is one of the most comprehensive investing research platforms available to individual investors, traders, financial advisors, and small hedge funds.
Our data covers the world, and includes fundamentals, analyst reports, ownership data and fund sentiment, options sentiment, insider trading, options flow, unusual options trades, and much more. Additionally, our exclusive stock picks are powered by advanced, backtested quantitative models for improved profits.
This story originally appeared on Fintel.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
